Avid Bioservices Inc (CDMO)

[Protector]

That is normal, Bavituximab is not the cancer fighting drug. It is the drug that makes cancer fighting possible by ALL other cancer fighting drugs that in their process have PS exposure as a disadvantage.

As such, Bavi can combine with most of those in the article because in their approach PS exposure is a fact. Even better, in the named category of PD-1, CTLA_4 etc of BMY, Roche, Merck, and INO it is SURE that they will need BAVI if they want to become the SOC (Standard of Treatment). And believe me they want!!!

BMY has the advantage of being approved (hence our CT with Bavi in the Cocktail). The BEST position to be in is too:

- Not have to compete as will BMY/Merck/Roche/INO and others will have to do because Bavi is the ONLY Upstream agent in existence.

- Being needed by ALL of them for them to win the race or at least keep up

- Have a diversified market (because Bavi works with Chemo as was proven and given how the MOA is understood now it will very probably score even better combined with Radio therapy)

- Have many potentials in other departments such as Digital Imaging (our IST) and Viral, Beta Bodies, etc, etc.

So the guy would better write an article on Bavituximab alone because he is going to need his lines!